BioTuesdays

Tag - STRO

Sutra-Biopharma-Logo

HCW starts Sutro Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...

Sutra-Biopharma-Logo

Stifel starts Sutro Biopharma at buy; PT $25

Stifel initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $25 price target. The stock closed at $16.35 on Dec. 2. Sutro is developing XpressCF, a cell-free protein-synthesis platform that...

Sutra-Biopharma-Logo

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...